BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

• Status: ENROLLING_BY_INVITATION
• Trial end date: 2028-12-01

Summary

There is no data comparing the effectiveness of the 4 most relevant first-line therapy programs for peripheral T-cell lymphomas (CHOEP, CHOP, CHEP-BV, CHP-BV) in a single study.

For the first time, the effectiveness and toxicity of various first-line PTCL therapy programs in patients with T-cell lymphoma will be analyzed in the conditions of a single medical center of the N.N.Petrov National Research Medical Center of Oncology and optimal therapeutic tactics will be determined, taking into account significant prognostic factors based on effectiveness and toxicity a specific chemotherapy regimen.

• Phase: PHASE3

Details

• Lead Sponsor: N.N. Petrov National Medical Research Center of Oncology
• Treatments: Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine